News
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...
This last patient was included because of the biological similarity between atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. 15 (39%) patients had high-risk cytogenetics ...
European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous ...
Michael Klim has revealed details about his five-year battle with a rare autoimmune disorder which left him unable to walk - ...
The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...
Stocktwits on MSN4d
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail AttentionNasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback